MOLLOY ANTHONY
Known title: Chief Lgl & Compliance OfficerCIK: 0001900012
Associated companies
Transaction History
| PCRX | ▼ Sell | Open Market | 4,521 | $174K | 6/6/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,267 | $87K | 6/5/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 546 | $21K | 1/5/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 158 | $6K | 1/4/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 7,950 | $0 | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 740 | $44K | 6/7/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,830 | $111K | 6/7/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,980 | $183K | 6/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 10,000 | $442K | 4/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 3,000 | $121K | 4/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 2,500 | $86K | 4/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 7,000 | $268K | 4/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 16,060 | $1.2M | 4/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 3,937 | $303K | 4/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,503 | $195K | 4/6/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 224 | $14K | 1/18/2022 | View on chart |
| PCRX | ▲ Buy | Grant | 2,000 | $0 | 1/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.